

# Sung-Yup Cho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3698245/publications.pdf>

Version: 2024-02-01

24  
papers

557  
citations

687363

13  
h-index

642732

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

758  
citing authors

#	ARTICLE	IF	CITATIONS
1	Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells. <i>Journal of Breast Cancer</i> , 2022, 25, 178.	1.9	3
2	Abstract 5477: Compound A, a fourth-generation allosteric inhibitor, a potent and highly selective EGFR with L858R activating and C797S resistance mutations for the treatment of NSCLC. <i>Cancer Research</i> , 2022, 82, 5477-5477.	0.9	0
3	Genome-scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib-resistant lung cancer. <i>Molecular Oncology</i> , 2021, 15, 487-502.	4.6	15
4	Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers. <i>Cancer Letters</i> , 2021, 497, 123-136.	7.2	8
5	Transglutaminase 2 crosslinks the glutathione S-transferase tag, impeding protein-protein interactions of the fused protein. <i>Experimental and Molecular Medicine</i> , 2021, 53, 115-124.	7.7	5
6	Transglutaminase 2 mediates transcriptional regulation through BAF250a polyamination. <i>Genes and Genomics</i> , 2021, 43, 333-342.	1.4	6
7	CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers. <i>Oncogene</i> , 2021, 40, 3287-3302.	5.9	18
8	Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. <i>Cancer Letters</i> , 2020, 495, 135-144.	7.2	8
9	Amplification of transglutaminase 2 enhances tumor-promoting inflammation in gastric cancers. <i>Experimental and Molecular Medicine</i> , 2020, 52, 854-864.	7.7	22
10	Transglutaminase 2 mediates hypoxia-induced selective mRNA translation via polyamination of 4EBPs. <i>Life Science Alliance</i> , 2020, 3, e201900565.	2.8	6
11	Significant allelic dropout phenomenon of Oncomine BRCA Research Assay on Ion Torrent S5. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, e124-e127.	2.3	1
12	Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments. <i>Blood</i> , 2018, 131, 1931-1941.	1.4	7
13	High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. <i>Experimental and Molecular Medicine</i> , 2017, 49, e317-e317.	7.7	37
14	A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2178-2190.	4.1	17
15	Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 12492-12497.	7.1	46
16	Intimal Hyperplasia in Loop-Injured Carotid Arteries Is Attenuated in Transglutaminase 2-Null Mice. <i>Journal of Korean Medical Science</i> , 2014, 29, 363.	2.5	5
17	Endoplasmic reticulum stress activates transglutaminase 2 leading to protein aggregation. <i>International Journal of Molecular Medicine</i> , 2014, 33, 849-855.	4.0	25
18	Doxorubicin Induces the Persistent Activation of Intracellular Transglutaminase 2 That Protects from Cell Death. <i>Molecules and Cells</i> , 2012, 33, 235-242.	2.6	21

#	ARTICLE	IF	CITATIONS
19	Transglutaminase 2 inhibits apoptosis induced by calcium overload through down-regulation of Bax. <i>Experimental and Molecular Medicine</i> , 2010, 42, 639.	7.7	44
20	Degradation of transglutaminase 2 by calcium-mediated ubiquitination responding to high oxidative stress. <i>FEBS Letters</i> , 2009, 583, 648-654.	2.8	21
21	TGF $\beta$ 2 mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation. <i>FASEB Journal</i> , 2008, 22, 2498-2507.	0.5	64
22	Cell Type-specific Activation of Intracellular Transglutaminase 2 by Oxidative Stress or Ultraviolet Irradiation. <i>Journal of Biological Chemistry</i> , 2004, 279, 15032-15039.	3.4	97
23	Transglutaminase 2 inhibits Rb binding of human papillomavirus E7 by incorporating polyamine. <i>EMBO Journal</i> , 2003, 22, 5273-5282.	7.8	54
24	Differential incorporation of biotinylated polyamines by transglutaminase 2. <i>FEBS Letters</i> , 2003, 534, 180-184.	2.8	27